The DOI matches its Crossref record.
Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Abstract
MUC1 is immunogenic in vivo and humoral and cellular immune responses against MUC1 have been detected in cancer patients. Our study explored the association of circulating anti‐MUC1 antibodies with clinicopathological parameters or patients' survival of pancreatic cancer. Serum specimens from 36 patients with invasive ductal carcinoma of the pancreas were subjected to enzyme immunoassay for anti‐MUC1 IgG or IgM antibodies. Serum levels of anti‐MUC1 IgG antibodies were significantly correlated with survival time (p = 0.0004), whereas neither those of anti‐MUC1 IgM nor anti‐Galα(1,3)Gal IgG antibodies, the latter known as natural antibodies cross‐reactive with MUC1, showed a given tendency. Some patients' sera with the higher antibody titer showed the reactivity with MUC1‐transfectants of cultured pancreatic cancer cells, but not with MUC1‐negative parental cells. When the samples were tentatively divided into 2 groups by the serum level of anti‐MUC1 IgG antibodies, the survival of patients was significantly longer in the group with optical density ≥0.3 than in that with optical density <0.3 (p = 0.008). Circulating anti‐MUC1 IgG antibody levels remained significant (HR, 0.03; 95% CI, 0.003–0.289; p = 0.0024) after multivariate analysis for pTNM stage, patient age and gender. These data suggest that circulating anti‐MUC1‐IgG antibody levels may be predictive for survival of pancreatic cancer patients. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Mucin-type O-glycosylation and its potential use in drug and vaccine development
Tarp, M. A., & Clausen, H. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.09.010 · Cited by 303
A systematic review of humoral immune responses against tumor antigens
Reuschenbach, M., von Knebel Doeberitz, M., & Wentzensen, N. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0733-4 · Cited by 280
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
Carmi, Y., Spitzer, M. H., Linde, I. L., Burt, B. M., Prestwood, T. R., Perlman, N., Davidson, M. G., Kenkel, J. A., Segal, E., Pusapati, G. V., et al. (2015) · Nature · doi:10.1038/nature14424 · Cited by 259
Metadata
- Authors
- Hamanaka, Y., Suehiro, Y., Fukui, M., Shikichi, K., Imai, K., & Hinoda, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-11-26
- Volume
- 103
- Issue
- 1
- Pages
- 97-100
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1991466268
- Cited by
- 165
- References
- 0
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. https://app.cochat.ai/papers/10.1002/ijc.10801
- The paper
- Hamanaka, Y., Suehiro, Y., Fukui, M., Shikichi, K., Imai, K., & Hinoda, Y. (2003). Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.10801
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.